hookipa pharma inc. is a clinical stage company developing products to prevent and cure infectious diseases and cancer. with this goal in mind we created unique and cutting-edge technologies which reprogram and stimulate the immune system. our arenavirus technologies, vaxwave®, a replication-deficient viral vector, and therat®, an attenuated replicating vector, induce potent pathogen-neutralizing antibodies and cd8+ t cells. both, vaxwave® and therat®, can be administered repeatedly while maintaining their efficacy. therat® induced cd8+ t cell responses to tumor antigens reach frequencies and potencies matching or exceeding those observed after adoptive t cell therapy. hookipa’s “off-the shelf” viral vectors are administered systemically. they target dendritic cells in vivo and activate the immune system. in immune-oncology, this mechanism enables to fight solid tumors systemically, both primary and secondary (metastatic). at hookipa we have successfully completed a phase 1 trial of a
Company profile
Ticker
HOOK
Exchange
Website
CEO
Jörn Aldag
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
815395687
HOOK stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
22 Mar 24
8-K
Results of Operations and Financial Condition
22 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
31 Jan 24
8-K
HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs
29 Jan 24
EFFECT
Notice of effectiveness
5 Jan 24
CORRESP
Correspondence with SEC
2 Jan 24
UPLOAD
Letter from SEC
29 Dec 23
S-3
Shelf registration
22 Dec 23
8-K
HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences
21 Dec 23
8-K
Departure of Directors or Certain Officers
1 Dec 23
Latest ownership filings
SC 13G/A
EcoR1 Capital, LLC
14 Feb 24
SC 13G/A
Redmile Group, LLC
14 Feb 24
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 24
SC 13G/A
GILEAD SCIENCES, INC.
22 Dec 23
3
Initial statement of insider ownership
22 Dec 23
SC 13G/A
FMR LLC
11 Sep 23
4
Reinhard Kandera
22 Aug 23
4
Reinhard Kandera
17 Aug 23
4
Jorn Aldag
11 Jul 23
4
Jorn Aldag
7 Jul 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 108.10 mm | 108.10 mm | 108.10 mm | 108.10 mm | 108.10 mm | 108.10 mm |
Cash burn (monthly) | 9.30 mm | (no burn) | 7.56 mm | 6.70 mm | 8.04 mm | 2.76 mm |
Cash used (since last report) | 55.47 mm | n/a | 45.05 mm | 39.94 mm | 47.93 mm | 16.48 mm |
Cash remaining | 52.62 mm | n/a | 63.04 mm | 68.16 mm | 60.16 mm | 91.62 mm |
Runway (months of cash) | 5.7 | n/a | 8.3 | 10.2 | 7.5 | 33.2 |
Institutional ownership, Q3 2023
50.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 46 |
Opened positions | 4 |
Closed positions | 13 |
Increased positions | 8 |
Reduced positions | 15 |
13F shares | Current |
---|---|
Total value | 21.50 bn |
Total shares | 48.73 mm |
Total puts | 2.40 k |
Total calls | 13.40 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
Baker Bros. Advisors | 8.07 mm | $4.97 bn |
Artal | 5.67 mm | $3.49 mm |
Knoll Capital Management | 5.52 mm | $3.40 bn |
EcoR1 Capital | 4.60 mm | $2.83 bn |
GILD Gilead Sciences | 3.76 mm | $6.47 mm |
Armistice Capital | 3.71 mm | $2.29 bn |
FMR | 3.36 mm | $2.07 bn |
Sofinnova Capital Vi FCPR | 3.14 mm | $4.05 mm |
Alyeska Investment | 3.11 mm | $1.92 bn |
Vanguard | 1.82 mm | $1.12 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
21 Aug 23 | Kandera Reinhard | Common Stock | Buy | Acquire P | No | No | 0.725 | 7,000 | 5.08 k | 43,092 |
16 Aug 23 | Kandera Reinhard | Common Stock | Buy | Acquire P | No | No | 0.714 | 8,000 | 5.71 k | 36,092 |
11 Jul 23 | Aldag Jorn | Common Stock | Buy | Acquire P | No | No | 0.8284 | 5,000 | 4.14 k | 71,952 |
7 Jul 23 | Aldag Jorn | Common Stock | Buy | Acquire P | No | No | 0.81 | 5,000 | 4.05 k | 66,952 |
30 Jun 23 | Kandera Reinhard | Common Stock | Buy | Acquire P | No | No | 0.88 | 12,000 | 10.56 k | 28,092 |
News
RBC Capital Reiterates Outperform on HOOKIPA Pharma, Maintains $5 Price Target
25 Mar 24
HC Wainwright & Co. Reiterates Buy on HOOKIPA Pharma, Maintains $6.5 Price Target
25 Mar 24
HOOKIPA Pharma: Q4 Earnings Insights
22 Mar 24
HOOKIPA Pharma Q4 EPS $(0.22) Misses $(0.19) Estimate, Sales $7.41M Beat $4.55M Estimate, Cash Balance of $117.5M
22 Mar 24
Roche Terminates Cancer Drug Pact With Repare Therapeutics, Its Second Walkout Within A Month
13 Feb 24
Press releases
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
22 Mar 24
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
6 Mar 24
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization
16 Jan 24